Purpose: Prior studies have identified risk factors which prognosticate severity of SARSCoV2 illness among hospitalized patients. Since the majority of patients first present to ambulatory care sites, there is a need to identify early predictors of disease progression in this population. Methods: This retrospective cohort study investigated the impact of underlying comorbid conditions on SARSCoV2 infection severity in the ambulatory setting. All patients who presented to a single federally qualified health center (FQHC) between March to May 2020 with a positive SARSCoV2 test were reviewed for inclusion. Patient demographics, symptomology, prior medical history, and outcomes were collected. Results: 301 patients were included, with nearly equal numbers of patients with (n=151) and without (n=150) underlying comorbidities. Overall, 269 patients (89%) had a mild outcome and 32 patients (11%) had a severe outcome. Advanced age (OR: 9.4 [95% CI: 3.4 to 27.4], p < 0.001) and male gender (OR: 3.2 [95% CI: 1.2 to 9.8], p = 0.02) were significant predictors of severe outcomes. Additionally, every obesity category (1: BMI = 30.0 to 34.9; 2: BMI = 35 to 39.9; 3: BMI = 40.0 plus) was associated with more severe outcomes compared to non-obese (OR: 3.5, p = 0.05; OR: 5.2, p = 0.03; OR: 13.9, p = 0.01). Compared to an HbA1C < 6, an HbA1C of 7.1 to 8.0 showed a clinically significant association. Conclusion: SARSCoV2 severity can be prognosticated in the ambulatory population by the presence and severity of preexisting comorbidities. Early identification and risk stratification of these comorbidities will allow clinicians to develop plans for closer monitoring to prevent severe illness.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB from Rutgers, Robert Wood Johnson Medical School gave ethical approval for this work after review of the institutional requirements. Protocol number for IRB: Pro2020001234

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

All data produced in the present work are contained in the manuscript